These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38204163)

  • 1. Application of improved GalNAc conjugation in development of cost-effective siRNA therapies targeting cardiovascular diseases.
    Li Q; Yin K; Ma HP; Liu HH; Li S; Luo X; Hu R; Zhang WW; Lv ZS; Niu XL; Gu MH; Li CL; Liu YS; Liu YJ; Li HB; Li N; Li C; Gu WW; Li JJ
    Mol Ther; 2024 Mar; 32(3):637-645. PubMed ID: 38204163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo.
    Rajeev KG; Nair JK; Jayaraman M; Charisse K; Taneja N; O'Shea J; Willoughby JL; Yucius K; Nguyen T; Shulga-Morskaya S; Milstein S; Liebow A; Querbes W; Borodovsky A; Fitzgerald K; Maier MA; Manoharan M
    Chembiochem; 2015 Apr; 16(6):903-8. PubMed ID: 25786782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing.
    Nair JK; Willoughby JL; Chan A; Charisse K; Alam MR; Wang Q; Hoekstra M; Kandasamy P; Kel'in AV; Milstein S; Taneja N; O'Shea J; Shaikh S; Zhang L; van der Sluis RJ; Jung ME; Akinc A; Hutabarat R; Kuchimanchi S; Fitzgerald K; Zimmermann T; van Berkel TJ; Maier MA; Rajeev KG; Manoharan M
    J Am Chem Soc; 2014 Dec; 136(49):16958-61. PubMed ID: 25434769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes.
    Matsuda S; Keiser K; Nair JK; Charisse K; Manoharan RM; Kretschmer P; Peng CG; V Kel'in A; Kandasamy P; Willoughby JL; Liebow A; Querbes W; Yucius K; Nguyen T; Milstein S; Maier MA; Rajeev KG; Manoharan M
    ACS Chem Biol; 2015 May; 10(5):1181-7. PubMed ID: 25730476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression.
    Willoughby JLS; Chan A; Sehgal A; Butler JS; Nair JK; Racie T; Shulga-Morskaya S; Nguyen T; Qian K; Yucius K; Charisse K; van Berkel TJC; Manoharan M; Rajeev KG; Maier MA; Jadhav V; Zimmermann TS
    Mol Ther; 2018 Jan; 26(1):105-114. PubMed ID: 28988716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro Drug-Drug Interaction Evaluation of GalNAc Conjugated siRNAs Against CYP450 Enzymes and Transporters.
    Ramsden D; Wu JT; Zerler B; Iqbal S; Jiang J; Clausen V; Aluri K; Gu Y; Dennin S; Kim J; Chong S
    Drug Metab Dispos; 2019 Oct; 47(10):1183-1194. PubMed ID: 31270142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of
    Ayyar VS; Song D; Zheng S; Carpenter T; Heald DL
    J Pharmacol Exp Ther; 2021 Nov; 379(2):134-146. PubMed ID: 34413198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates.
    Foster DJ; Brown CR; Shaikh S; Trapp C; Schlegel MK; Qian K; Sehgal A; Rajeev KG; Jadhav V; Manoharan M; Kuchimanchi S; Maier MA; Milstein S
    Mol Ther; 2018 Mar; 26(3):708-717. PubMed ID: 29456020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolically Stable Anomeric Linkages Containing GalNAc-siRNA Conjugates: An Interplay among ASGPR, Glycosidase, and RISC Pathways.
    Kandasamy P; Mori S; Matsuda S; Erande N; Datta D; Willoughby JLS; Taneja N; O'Shea J; Bisbe A; Manoharan RM; Yucius K; Nguyen T; Indrakanti R; Gupta S; Gilbert JA; Racie T; Chan A; Liu J; Hutabarat R; Nair JK; Charisse K; Maier MA; Rajeev KG; Egli M; Manoharan M
    J Med Chem; 2023 Feb; 66(4):2506-2523. PubMed ID: 36757090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Less Is More: Novel Hepatocyte-Targeted siRNA Conjugates for Treatment of Liver-Related Disorders.
    Weingärtner A; Bethge L; Weiss L; Sternberger M; Lindholm MW
    Mol Ther Nucleic Acids; 2020 Sep; 21():242-250. PubMed ID: 32590173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate.
    Zimmermann TS; Karsten V; Chan A; Chiesa J; Boyce M; Bettencourt BR; Hutabarat R; Nochur S; Vaishnaw A; Gollob J
    Mol Ther; 2017 Jan; 25(1):71-78. PubMed ID: 28129130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of
    McDougall R; Ramsden D; Agarwal S; Agarwal S; Aluri K; Arciprete M; Brown C; Castellanos-Rizaldos E; Charisse K; Chong S; Cichocki J; Fitzgerald K; Goel V; Gu Y; Guenther D; Habtemariam B; Jadhav V; Janas M; Jayaraman M; Kurz J; Li J; Liu J; Liu X; Liou S; Maclauchlin C; Maier M; Manoharan M; Nair JK; Robbie G; Schmidt K; Smith P; Theile C; Vaishnaw A; Waldron S; Xu Y; Zhang X; Zlatev I; Wu JT
    Drug Metab Dispos; 2022 Jun; 50(6):781-797. PubMed ID: 34154993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Serum Proteins on the Uptake and RNAi Activity of GalNAc-Conjugated siRNAs.
    Agarwal S; Allard R; Darcy J; Chigas S; Gu Y; Nguyen T; Bond S; Chong S; Wu JT; Janas MM
    Nucleic Acid Ther; 2021 Aug; 31(4):309-315. PubMed ID: 33861634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure to siRNA-GalNAc Conjugates in Systems of the Standard Test Battery for Genotoxicity.
    Janas MM; Jiang Y; Duncan RG; Hayes AN; Liu J; Kasperkovitz PV; Placke ME; Barros SA
    Nucleic Acid Ther; 2016 Dec; 26(6):363-371. PubMed ID: 27387336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand Conjugated Multimeric siRNAs Enable Enhanced Uptake and Multiplexed Gene Silencing.
    Brown JM; Dahlman JE; Neuman KK; Prata CAH; Krampert MC; Hadwiger PM; Vornlocher HP
    Nucleic Acid Ther; 2019 Oct; 29(5):231-244. PubMed ID: 31393218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel diamine-scaffold based
    Li Q; Dong M; Chen P
    RSC Adv; 2024 May; 14(25):17461-17466. PubMed ID: 38818366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Pharmacokinetics of N-Acetylgalactosamine-Conjugated Small-Interfering Ribonucleic Acids (GalNAc-Conjugated siRNAs).
    Sten S; Cardilin T; Antonsson M; Gennemark P
    Clin Pharmacokinet; 2023 Dec; 62(12):1661-1672. PubMed ID: 37824025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Cluster and Monomer-Based GalNAc Structures Induce Effective Uptake of siRNAs in Vitro and in Vivo.
    Sharma VK; Osborn MF; Hassler MR; Echeverria D; Ly S; Ulashchik EA; Martynenko-Makaev YV; Shmanai VV; Zatsepin TS; Khvorova A; Watts JK
    Bioconjug Chem; 2018 Jul; 29(7):2478-2488. PubMed ID: 29898368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-Reactive Polyclonal Antibodies Raised Against GalNAc-Conjugated siRNA Recognize Mostly the GalNAc Moiety.
    Ballman KK; Peek VL; Sloan JH; Li J; Konrad RJ; Wen Y
    AAPS J; 2024 Apr; 26(3):41. PubMed ID: 38570436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solid-phase synthesis of 5'-triantennary N-acetylgalactosamine conjugated antisense oligonucleotides using phosphoramidite chemistry.
    Prakash TP; Brad Wan W; Low A; Yu J; Chappell AE; Gaus H; Kinberger GA; Østergaard ME; Migawa MT; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4127-30. PubMed ID: 26299345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.